API | asunaprevir

asunaprevir Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Asunaprevir is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013. ^Wikipedia

Chemistry

SMILES: C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
InChIKey: XRWSZZJLZRKHHD-WVWIJVSJSA-N
Mol. Mass: 748.3
ALogP: 3.85 Partition coefficient
ChEMBL Molecule:
asunaprevir

More Chemistry

Pharmacology

Mechanisms of Action:
- Genome polyprotein (Hepatitis C virus) ^UniProt
- Genome polyprotein (Hepatitis C virus) ^UniProt
- Non-structural protein 4A (Hepatitis C virus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Oral
Pro Drug: No

asunaprevir | bms-650032 | sunvepra

Organizations (37)

Research & Development (37)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (1)

Hepatitis C

Experimental Indications - Clinical Trial Phases 1-4 (7)

Fibrosis (Phase 2)

Hepacivirus (Phase 3)

Hepatic Insufficiency (Phase 1)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

HIV Infections (Phase 2)

Osteoarthritis, Hip (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 44
# of Trial Organizations: 37

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue